Compare Chevron Corp (CVX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Inovio Pharmaceuticals Inc — how do they compare? Chevron Corp trades at $196.6 (market cap $385.77B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Chevron Corp is far larger — about 4911.1× Inovio Pharmaceuticals Inc's market cap, and Chevron Corp pays a 3.62% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CVX | INO | |
|---|---|---|
Market Cap | $385.77B | $78.55M |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $2.87 |
52-Week Low | $146.72 | $0.66 |
Enterprise Value | $414.31B | $49.56M |
Dividend Yield | 3.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $194.9, up 4.47% today, with a bullish technical signal and strong analyst support. Recent earnings consistently beat expectations, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and 12.25% ROE, supported by a $13.8 billion investment in Argentina's Vaca Muerta shale project announced on June 2, 2026 (Reuters).
Outlook remains positive with a consensus price target of $214.25, implying 10% upside. Risks include declining revenue from $184.43B in 2025 and exposure to volatile oil prices, but high oil prices and strategic expansions provide growth catalysts. The stock offers a steady dividend of $1.78 per half-year.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
